Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTR

Annals of the American Thoracic Society

Volumn 14, Issue 2, 2017, Pages 213-219

  Rowe, Steven M ^a   McColley, Susanna A ^b   Rietschel, Ernst ^c   Li, Xiaolei ^d   Bell, Scott C ^e   Konstan, Michael W ^f   Marigowda, Gautham ^d   Waltz, David ^d   Boyle, Michael P ^g  

^a and Clinical Center   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d VERTEX PHARMACEUTICALS   (United States)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Adverse events; Percent predicted forced expiratory volume in 1 second; Sweat chloride

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR PLUS LUMACAFTOR; 1,3 BENZODIOXOLE DERIVATIVE; AMINOPHENOL DERIVATIVE; AMINOPYRIDINE DERIVATIVE; CFTR PROTEIN, HUMAN; IVACAFTOR; LUMACAFTOR; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CHEST TIGHTNESS; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DISEASE MARKER; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HETEROZYGOSITY; HUMAN; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SWEAT; SYMPTOMATOLOGY; UPPER ABDOMINAL PAIN; ADOLESCENT; AUSTRALIA; CHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EUROPE; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AMINOPHENOLS; AMINOPYRIDINES; AUSTRALIA; BENZODIOXOLES; BODY MASS INDEX; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUTATION; QUINOLONES; SWEAT; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 85014753482     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201609-689OC     Document Type: Article

References (17)

1. Berger HA, Anderson MP, Gregory RJ, Thompson S, Howard PW, Maurer RA,Mulligan R, Smith AE, WelshMJ. Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel. J Clin Invest 1991;88:1422-1431.
2. Choi JY, Muallem D, Kiselyov K, Lee MG, Thomas PJ, Muallem S. Aberrant CFTR-dependent HCO3 2 transport in mutations associated with cystic fibrosis. Nature 2001;410:94-97.
3. Derichs N. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Eur Respir Rev 2013;22:58-65.
4. Cystic Fibrosis Foundation. Patient registry: annual data report 2014. Bethesda, MD: Cystic Fibrosis Foundation; 2014 [accessed 2016 May 19]. Available from: https://www.cff.org/2014-Annual-Data-Report.pdf
5. Clinical and Functional Translation of CFTR (CFTR2). Summary for F508del mutation. Baltimore: CFTR2 Team; 2016 [accessed 2016 May 19]. Available from: http://www.cftr2.org/mutation.php? view=general&mutation-id=1
6. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (DF508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 1994;13:6076-6086.
7. Van Goor F, Straley KS, Cao D, Gonzá lez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, et al. Rescue of DF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290:L1117-L1130.
8. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373: 1891-1904.
9. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011;108: 18843-18848.
10. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106:18825-18830.
11. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014;2:527-538.
12. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, et al.; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373:220-231.
13. Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP. Effect of 8 weeks of lumacaftor in combination with ivacaftor in patients with CF and heterozygous for the F508del CFTR mutation [abstract 254]. Pediatr Pulmonol 2014; 49(Suppl 38):306.
14. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.
15. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15: 75-88.
16. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135: 1610-1618.
17. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, et al.; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014; 190:175-184.